Endometriosis has long confounded medicine not merely because it is difficult to detect, but because it reliably returns. A study published in Nature now proposes that the disease's persistence may be rooted in how its misplaced cells generate energy — and that interrupting that energy supply, using a compound called Rotenone, can reduce lesions and scarring in experimental models. The finding reframes endometriosis as a metabolic condition as much as a hormonal or inflammatory one, opening a corridor of inquiry that conventional therapies have not yet entered.
Blocking Mitochondrial Energy Production Shows Promise in Treating Endometriosis
Starving the disease of energy at the cellular level
Mark
So the researchers found that endometriosis cells are basically running on overdrive metabolically. What does that actually mean for a patient?
Mimi
It means the stromal cells in endometriosis lesions are producing far more ATP—cellular energy—than they should be. That extra energy fuels proliferation, migration, and the invasion of surrounding tissue. It's like the disease has found a way to supercharge itself.
Luke
But we should be careful here. This is observed in tissue samples and in lab-grown cells. We don't yet know if blocking this pathway in a living human body would have the same effect.
Mark
Right. So Rotenone is the drug they tested. How does it work?
Mimi
It's a mitochondrial complex I inhibitor. Complex I is the first step in the oxidative phosphorylation chain—the machinery that makes ATP. Block it, and you starve the cell of energy. In the lab, it stopped endometriosis cells from multiplying and spreading.
Luke
And in the animal models, it reduced cystic lesions and fibrosis. But animal models of endometriosis are surgical implants, not the naturally occurring disease. The biology might differ.
Mark
What about the hormone levels? The study mentions estradiol and progesterone were restored.
Mimi
Yes. In the treated mice, those hormone levels moved closer to normal. That's significant because endometriosis involves dysregulation of estrogen and progesterone signaling. If metabolic inhibition can help restore hormonal balance, that's a second mechanism of benefit.
Luke
Though we should note: the study doesn't explain why blocking mitochondrial energy production would normalize hormones. That's an observation, not a mechanistic explanation. It's worth investigating further.
Mark
So what's the next step?
Mimi
Human trials, presumably. But first, probably more work in animal models to understand safety, dosing, and whether the effects hold up over time.
Luke
And whether Rotenone itself is the right drug. It's a pesticide. There may be other complex I inhibitors with better safety profiles for human use.
El Pulso
- Endometriosis affects millions of women worldwide, yet high recurrence rates and limited treatments leave many without lasting relief.
- Single-cell RNA sequencing exposed a hidden driver: a specific population of stromal cells in diseased tissue running their mitochondria at abnormally high output, flooding lesions with cellular energy.
- Rotenone, a mitochondrial complex I inhibitor, cut off that energy supply in lab cultures — halting the cells' ability to proliferate, migrate, and invade surrounding tissue.
- In mouse models with surgically induced endometriosis, Rotenone shrank cystic lesions, reduced organ adhesions, eased fibrosis, and nudged dysregulated hormones back toward normal ranges.
- The research has not yet reached human trials, but the coherence of findings across sequencing, biochemical, and whole-organism levels positions metabolic modulation as a credible new therapeutic direction.
Endometriosis has long confounded medicine not merely because it is difficult to detect, but because it reliably returns. A study published in Nature now proposes that the disease's persistence may be rooted in how its misplaced cells generate energy — and that interrupting that energy supply, using a compound called Rotenone, can reduce lesions and scarring in experimental models. The finding reframes endometriosis as a metabolic condition as much as a hormonal or inflammatory one, opening a corridor of inquiry that conventional therapies have not yet entered.
Endometriosis — tissue resembling the uterine lining growing where it should not — has long resisted medicine's best efforts. Diagnosis is slow, recurrence is common, and existing treatments address symptoms rather than causes. A study now published in Nature proposes a different lens: the disease may be powered, quite literally, by an overactive energy metabolism in its cells.
Using single-cell RNA sequencing across twelve patient samples and healthy controls, researchers mapped the cellular composition of endometriosis tissue. They found elevated proportions of stromal, immune, and myeloid cells — and within the stromal population, a cycling subset uniquely enriched in diseased tissue. This subset carried a genetic signature dominated by oxidative phosphorylation, the mitochondrial process that converts nutrients into ATP, the cell's primary fuel. The ectopic lesions themselves confirmed the picture: disrupted architecture, heavy collagen accumulation, and markedly elevated activity at mitochondrial complex I, the pathway's first step.
The researchers tested Rotenone, a compound that blocks complex I, against stromal cells cultured from endometriosis lesions. It suppressed proliferation, migration, and invasion while reducing ATP production and the expression of oxidative phosphorylation proteins — starving the cells of the energy driving their aggression.
In mice with surgically induced endometriosis, the effects extended to the tissue level. Rotenone reduced the number and size of ovarian cystic lesions, decreased organ adhesions, and significantly diminished fibrosis — the scarring that compounds the disease over time. Estradiol and progesterone levels moved closer to normal, and the metabolic signature linking stromal markers to energy-pathway proteins faded.
The path to human treatment remains long, and this work has not yet left the laboratory. But the consistency across sequencing data, cell culture, and animal models suggests oxidative phosphorylation is genuinely central to how endometriosis progresses. If that holds in clinical trials, targeting cellular energy metabolism could offer something current therapies do not: an attack on the disease's fuel source rather than its downstream effects.
Endometriosis remains one of medicine's stubborn puzzles. The condition, in which tissue similar to the uterine lining grows outside the uterus, affects millions of women worldwide, yet diagnosis is difficult and recurrence is common. A new study published in Nature suggests the problem may lie not in the tissue itself, but in how that tissue powers itself—and that shutting down one particular energy-production pathway could offer a way forward.
Researchers used single-cell RNA sequencing to map the cellular landscape of endometriosis tissue, examining twelve endometrial samples from patients with the condition and comparing them to healthy controls. What emerged was a cellular imbalance: endometriosis tissue contained elevated proportions of stromal cells (the connective tissue framework), immune cells, and myeloid cells. More telling, a subset of stromal cells called the eStromal_cycling population was significantly enriched in diseased tissue. These cells showed a distinctive genetic signature—one heavily linked to oxidative phosphorylation, the mitochondrial pathway that converts nutrients into adenosine triphosphate, or ATP, the cell's energy currency.
The ectopic lesions themselves—the misplaced tissue growths—bore the marks of this metabolic overdrive. Under microscopic examination, they showed disrupted architecture, excessive collagen buildup, and markedly elevated activity in mitochondrial complex I, the first step in the oxidative phosphorylation chain. ATP levels were correspondingly high. The researchers found that proteins involved in this energy pathway clustered together with vimentin, a marker of stromal cells, in the diseased tissue.
This observation suggested a therapeutic angle. The team tested Rotenone, a compound that blocks mitochondrial complex I, on endometrial stromal cells extracted from endometriosis lesions grown in laboratory culture. The results were direct: Rotenone suppressed the cells' ability to proliferate, migrate, and invade surrounding tissue. It also reduced complex I activity, ATP production, and the expression of oxidative phosphorylation proteins. The drug worked at the metabolic level, starving these cells of energy.
When the researchers moved to animal models—mice with surgically induced endometriosis—the effects translated to tissue-level changes. Rotenone treatment reduced the number and size of ovarian cystic lesions and decreased adhesions between organs. Fibrosis, the scarring that makes endometriosis progressively worse, declined significantly. Hormone levels shifted: estradiol and progesterone, which are dysregulated in endometriosis, moved closer to normal. The co-localization of oxidative phosphorylation proteins and stromal markers diminished, suggesting the metabolic signature of disease was being reversed.
The pathway from bench to bedside remains long. This work was conducted in cell culture and animal models, not in human patients. But the consistency of the findings—from single-cell sequencing to biochemical assays to whole-organism effects—suggests the oxidative phosphorylation pathway is genuinely central to how endometriosis progresses and causes fibrosis. If that holds true in human trials, metabolic modulation could represent a fundamentally different approach to a condition that has resisted conventional treatment. Rather than targeting inflammation or hormone signaling, as most current therapies do, this strategy would attack the energy metabolism that fuels the disease at the cellular level.
Citas Notables
Activation of the oxidative phosphorylation pathway in stromal cells is associated with disease progression and fibrosis— Study findings
Quieres la nota completa?
Lee el original en Nature ↗
Health & Medicine